MedDataX Logo

Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta

NCT ID: NCT04945811

Last Updated: 2021-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-01

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Serum Interleukin-6 and Procalcitonin of 100 consenting COVID 19 positive patients from April 2020 - May 2021 were assessed at Pathology department CMH Quetta and the results were correlated with severity of lung involvement on HRCT Chest

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population

NCT04568850

Covid19
UNKNOWN

Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2

NCT04655521

COVID-19 SARS-CoV-2 Viral Infection
COMPLETED

Monitoring the IgG/IgM Antibodies in COVID-19 Patients

NCT04810117

COVID-19 Infections
COMPLETED

International Study of Inflammation in COVID-19

NCT04818866

Covid19 Outcome, Fatal Respiratory Failure +2 more
COMPLETED

Evaluating the Response of the Immune System of People with Long COVID (post SARS-CoV-2)

NCT05131594

COVID-19
ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: To explore the relation between Interleukin-6 and Procalcitonin with COVID severity on HRCT Chest Study Design: Randomized Control Trial (Clinical Trials. gov Identifier: NCT04798391) Place and duration of study: Pathology, Radiology \& ENT Department CMH Quetta from April 2020 - May 2021 Methodology: Serum Interleukin-6 and Procalcitonin of 100 consenting COVID 19 positive patients from April 2020 - May 2021 were assessed at Pathology department CMH Quetta and the results were correlated with severity of lung involvement on HRCT Chest Results: Serum Interlukin-6 levels were raised in 97 (97%) patients with mean levels of 20.43 + 19.66 (pg/ml). Serum procalcitonin levels were raised in 95 (95%) patients with mean levels of 0.4331 + 0.24 (ng/ml). A P value of \<0.001 was calculated on Independent Sample T-test for both serum interlukin-6 and serum procalcitonin as correlated with severity of lung involvement on HRCT Chest.

Conclusion: Interlukin-6 and procalcitonin are excellent biomarkers for diagnosis and predicting severity of COVID19 pneumonia.

Keywords: Covid19 pneumonia, Interlukin-6, procalcitonin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Positive Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interlukein 6 and procalcitonin

Interlukein 6 and procalcitonin levels in COVID 19 patients

Group Type EXPERIMENTAL

Interlukein 6 and procalcitonin serum levels

Intervention Type DIAGNOSTIC_TEST

Blood tests

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interlukein 6 and procalcitonin serum levels

Blood tests

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* positive PCR of COVID 19

Exclusion Criteria

* NEGATIVE PCR of COVID 19
Minimum Eligible Age

38 Years

Maximum Eligible Age

71 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

FARAH AFZAL

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

FARAH AFZAL

CLASSIFIED SPECIALIST

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cmh Quetta

Quetta, Balochistan, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMHQ3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prospective Studies on Immunopathogenesis of Liver Fibrosis
NCT04943978 RECRUITING
Gene Polymorphism of IL17 and IL 23
NCT04948515 COMPLETED
Characterization of the Immunometabolic Signature in Long COVID-19.
NCT05758480 COMPLETED NA
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
NCT05858502 RECRUITING NA
Seroconversion in COVID-19 Recovered Population
NCT04558385 COMPLETED
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
NCT04587323 RECRUITING
Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
NCT05484700 UNKNOWN
Identification and Verification of Neutrophil Extracellular Trap Net Related Markers in Acute-on-chronic Liver Failure
NCT05909319 UNKNOWN
Autoimmunity Contributes to the Severe Progression of COVID-19
NCT04967781 COMPLETED
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
NCT04520880 UNKNOWN
Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method
NCT04429620 UNKNOWN
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer.
NCT06080750 UNKNOWN
Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
NCT00001257 TERMINATED
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
NCT04817553 COMPLETED
Neutralizing Antibody Level After COVID-19 Vaccination
NCT05083026 UNKNOWN
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
NCT07238114 ACTIVE_NOT_RECRUITING
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
NCT04540484 COMPLETED
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
NCT04562285 COMPLETED
SARS-CoV-2 IgG and IgM Serologic Assays
NCT04562246 COMPLETED
Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients
NCT07003451 NOT_YET_RECRUITING
How Important Are Hematological Parameters in the Prognosis of Severe Covid-19 Patients?
NCT05650944 COMPLETED
COVID-19 and Nonalcoholic Fatty Liver Disease
NCT04982328 COMPLETED
COVID-19 IgG Antibodies in the Serum of Recovered Patients
NCT04470414 UNKNOWN
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).
NCT04632732 COMPLETED
Profiling the Inflammatory Cascade of COVID-19
NCT06511024 COMPLETED